Can a diabetes drug help teens lose weight? new study investigates

NCT ID NCT06852391

Recruiting now Disease control Sponsor: McMaster University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether adding the drug semaglutide (Wegovy®) to a behavioral lifestyle program helps teenagers with obesity lose weight and adapt their metabolism. About 74 teens aged 12-17 will be split into two groups: one gets the lifestyle program alone for 6 months, then adds semaglutide; the other gets both from the start. Researchers will measure how the body's energy use changes, aiming to find better weight management strategies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide (Wegovy®)
What this could lead to: If successful, this could show that combining semaglutide with a lifestyle program is more effective for weight management in teens than lifestyle changes alone.
What could go wrong: This is a small, early-phase study (74 participants) focused on metabolic changes, not long-term weight loss or safety. Semaglutide can cause side effects like nausea and vomiting, and results may not apply to all teens with obesity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY (DISORDER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY (DISORDER)

Contacts and locations

Locations

McMaster University
RECRUITING

Hamilton, Ontario, L8S 4L8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.